View Exam | PowerPak

1. Prevalence of CMV seropositivity among the U.S. population is approximately:

A. 10% B. 33% C. 50% D. >80% E. Unsure

2. Reactivation of symptomatic CMV disease is:

A. common in adults who were infected at an early age due to long viral latency periods B. rare in immunocompetent adults, but can occur in immunocompromised individuals C. similar to patterns seen with other Herpesviruses such as herpes zoster or herpes simplex D. triggered by respiratory illnesses or stress E. Unsure

3. In an adult who has undergone a CMV antigen test, the most reliable evidence for primary infection would be:

A. Positive CMV IgG on ELISA test B. Positive CMV IgM on ELISA test C. IgM positive results in combination with low IgG avidity D. All of the above E. Unsure

4. The preferred testing method for CMV to determine the need for treatment or prophylaxis in patients undergoing a transplant procedure is:

A. complete blood count (CBC) with differential B. viral culture for CMV viremia C. ELISA for CMV antigen in serum (IgM or IgG) D. quantitative nucleic acid test (QNAT) E. Unsure

5. Your patient is D+/R– for an upcoming transplant. Into which risk category would this patient for risk of CMV infection following the procedure?

A. low risk for CMV; monitoring is recommended but not prophylaxis B. low-moderate risk; monitoring recommended C. high-moderate risk; patient could be susceptible to CMV superinfection D. high risk for CMV; patient should receive pre-emptive therapy E. Unsure

6. Antiviral therapies approved for prophylactic treatment of CMV in patients undergoing solid organ transplant include:

A. oral valganciclovir and oral ganciclovir B. oral valganciclovir and IV ganciclovir C. IV valganciclovir and oral ganciclovir D. IV valganciclovir and letermovir E. Unsure

7. In patients undergoing HSCT, the therapy associated with lower risk of leukopenia and other hematologic adverse effects is:

A. valganciclovir B. ganciclovir C. letermovir D. all agents have similar safety profiles E. Unsure

8. The adverse effect limiting the use of foscarnet and cidofovir in the treatment of active CMV infection is:

A. nephrotoxicity B. neurotoxicity C. leukopenia D. elevated infection risk E. Unsure

9. Following HSCT, European guidelines recommend that patients be monitored for CMV infection:

A. weekly for 60 days after transplant; then every 6 months thereafter B. weekly for the first 100 days after transplant; longer for high-risk populations C. monthly for a period of 1 year after the transplant D. monthly, only if the patient is high or moderate risk for CMV E. Unsure

10. Pharmacists from Cleveland Clinic were able to demonstrate improved outcomes in transplant patients by initiating a pharmacist-driven intervention program. The interventions consisted of:

A. antimicrobial stewardship program and optimization of medication therapies B. patient assistance programs (PAP) C. patient and healthcare provider awareness about CMV risk factors and treatment D. adjusting the formulary to provide a wider range of prophylactic therapies E. Unsure

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Prevalence of CMV seropositivity among the U.S. population is approximately:

2. Reactivation of symptomatic CMV disease is:

3. In an adult who has undergone a CMV antigen test, the most reliable evidence for primary infection would be:

4. The preferred testing method for CMV to determine the need for treatment or prophylaxis in patients undergoing a transplant procedure is:

5. Your patient is D+/R– for an upcoming transplant. Into which risk category would this patient for risk of CMV infection following the procedure?

6. Antiviral therapies approved for prophylactic treatment of CMV in patients undergoing solid organ transplant include:

7. In patients undergoing HSCT, the therapy associated with lower risk of leukopenia and other hematologic adverse effects is:

8. The adverse effect limiting the use of foscarnet and cidofovir in the treatment of active CMV infection is:

9. Following HSCT, European guidelines recommend that patients be monitored for CMV infection:

10. Pharmacists from Cleveland Clinic were able to demonstrate improved outcomes in transplant patients by initiating a pharmacist-driven intervention program. The interventions consisted of:

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Prevalence of CMV seropositivity among the U.S. population is approximately:

2. Reactivation of symptomatic CMV disease is:

3. In an adult who has undergone a CMV antigen test, the most reliable evidence for primary infection would be:

4. The preferred testing method for CMV to determine the need for treatment or prophylaxis in patients undergoing a transplant procedure is:

5. Your patient is D+/R– for an upcoming transplant. Into which risk category would this patient for risk of CMV infection following the procedure?

6. Antiviral therapies approved for prophylactic treatment of CMV in patients undergoing solid organ transplant include:

7. In patients undergoing HSCT, the therapy associated with lower risk of leukopenia and other hematologic adverse effects is:

8. The adverse effect limiting the use of foscarnet and cidofovir in the treatment of active CMV infection is:

9. Following HSCT, European guidelines recommend that patients be monitored for CMV infection:

10. Pharmacists from Cleveland Clinic were able to demonstrate improved outcomes in transplant patients by initiating a pharmacist-driven intervention program. The interventions consisted of:

« Return to Activity

Customers who Purchased
this Activity also Purchased